相关实验视频
Updated: Jul 24, 2026

Calcium Imaging of Cortical Neurons using Fura-2 AM
Published on: January 19, 2009
在芬太尼自给药升级后,中心杏仁体活动的成像
Samantha G Malone1, Navid S Tavakoli2, Peggy S Keller1
1University of Kentucky, Department of Psychology, Lexington, KY, USA.
增加芬太尼的摄入量会在戒断期间改变中枢杏仁体神经元的活动. 这个大脑区域的大脑区域.
科学领域:
- 神经科学是一个神经科学.
- 神经药理学神经药理学
- 阿片类药物研究研究
背景情况:
- 中枢桃体 (CeA) 在阿片类药物成和复发中发挥着至关重要的作用.
- 了解慢性阿片类药物暴露如何改变CeA中的神经元功能对于开发有效治疗至关重要.
研究的目的:
- 调查升级芬太尼自给药 (SA) 对CeA神经元活动的影响.
- 为了检查这些变化在急性 (17小时) 和长时间 (30天) 禁食期间.
主要方法:
- 老鼠接受了短途接入 (ShA),其次是长途接入 (LgA) 芬太尼或盐酸自给.
- 对CeA神经元的ex vivo成像是在急性或长期戒断后的脑切片中进行的.
- 评估神经元活动是响应急性芬太尼的应用.
主要成果:
- 暴露于芬太尼的老鼠在戒药30天后显示基底CeA神经活动降低.
- 急性芬太尼应用抑制了所有大鼠的CeA神经元活动.
- 芬太尼对CeA活性的抑制作用在急性戒断期间减弱,但在长期戒断期间在芬太尼SA大鼠中增强,与对照组相比.
结论:
- 升级的芬太尼自给药诱导了CeA神经元刺激性的持久变化.
- 在CEA中对芬太尼的神经元反应的这些改变可能会在长期戒断期间导致阿片类药物复发的脆弱性.
更多相关视频
08:07Simultaneous Detection of c-Fos Activation from Mesolimbic and Mesocortical Dopamine Reward Sites Following Naive Sugar and Fat Ingestion in Rats
Published on: August 24, 2016
09:39Successful In vivo Calcium Imaging with a Head-Mount Miniaturized Microscope in the Amygdala of Freely Behaving Mouse
Published on: August 26, 2020
相关概念视频
Tissue Renewal without Stem Cells
However, failure of such a system...
Liver Regeneration
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are large...
Drug Biotransformation: Overview
Centrally Acting Muscle Relaxants: Therapeutic Uses
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
Heart Failure Drugs: Inotropic Agents
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...